Atorvastatin/choline-fenofibrate - Chong Kun Dang

Drug Profile

Atorvastatin/choline-fenofibrate - Chong Kun Dang

Alternative Names: Atorvastatin calcium trihydrate/choline fenofibrate; CKD-337; Fenofibrate/atorvastatin - Chong Kun Dang

Latest Information Update: 03 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chong Kun Dang
  • Class Amides; Antihyperlipidaemics; Fibric acid derivatives; Fluorobenzenes; Heptanoic acids; Pyrroles
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyslipidaemias

Most Recent Events

  • 07 Nov 2017 Chong Kun Dang completes a phase I trial for Dyslipidaemias (In volunteers) in South Korea (NCT03382756)
  • 16 Oct 2017 Chong Kun Dang initiates enrolment in a phase I trial for Dyslipidaemias (In volunteers) in South Korea (NCT03382756)
  • 05 Oct 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top